Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? :Specific Phenotypes of Disease Progression

Annals of the American Thoracic Society

Volumn 15, Issue 12, 2018, Pages 1427-1433

  Guler, Sabina A ^a,d,e   Winstone, Tiffany A ^a,e   Murphy, Darra ^b   Hague, Cameron ^b   Soon, Jeanette ^b   Sulaiman, Nada ^b   Li, Kathy H ^c,e   Dunne, James ^e   Wilcox, Pearce G ^e   Ryerson, Christopher J ^a,e  

^a The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^b Department of Radiology ^*  (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BERN   (Switzerland)

^e ST PAUL S HOSPITAL   (Canada)

Author keywords

Phenotype; Pulmonary fibrosis; Respiratory function tests; Systemic scleroderma

Indexed keywords

CARBON MONOXIDE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GROUPS BY AGE; HUMAN; INTERSTITIAL LUNG DISEASE; LONG TERM SURVIVAL; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PHENOTYPE; PROGNOSIS; PULMONARY HYPERTENSION; SEX DIFFERENCE; SMOKING; SYSTEMIC SCLEROSIS; AGED; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL RATE; TIME FACTOR; VITAL CAPACITY;

ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PHENOTYPE; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TIME FACTORS; VITAL CAPACITY;

EID: 85057539907     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201806-362OC     Document Type: Article

References (32)

1. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007;66:754-763.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-944.
3. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-1289.
4. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al.; EUSTAR Group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017;76:1897-1905.
5. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014;146:422-436.
6. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-1254.
7. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, et al. Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model. Chest 2017;152:999-1007.
8. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602.
9. Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol 2015;33(4, Suppl 91):S111-S116.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
11. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism Collaborative initiative. Arthritis Rheum 2013;65:2737-2747.
12. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-735.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
14. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-522.
15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
16. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384-1387.
17. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-243.
18. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-719.
19. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666.
20. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al.; EUSTAR Rituximab Study Group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015;74:1188-1194.
21. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018;77:212-220.
22. Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017;4:e000212.
23. ClinicalTrials.gov. A study of pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease [2020]. Available from: https://ClinicalTrials.gov/show/NCT03099187.
24. Caron M, Hoa S, Hudson M, Schwartzman K, Steele R. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev 2018;27:170102.
25. Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, et al. Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med [online ahead of print] 3 Nov 2017; DOI: 10.1164/rccm.201709-1845OC.
26. Ryerson CJ, Denton CP. The fine line between success and failure in scleroderma lung fibrosis trials. Am J Respir Crit Care Med 2018;197: 553-554.
27. Le Gouellec N, Duhamel A, Perez T, Hachulla AL, Sobanski V, Faivre JB, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS One 2017;12:e0181692.
28. Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, et al.; EUSTAR Co-workers on Behalf of the DeSScipher Project Research Group within the EUSTAR Network. Systemic sclerosis associated interstitial lung disease: individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther 2018;20:17.
29. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al.; DETECT Study Group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340-1349.
30. Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015;17:372.
31. Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009;61:958-965.
32. Ryerson CJ, O'Connor D, Dunne JV, Schooley F, Hague CJ, Murphy D, et al. Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 2015;148:1268-1275.